Lipitor & Plavix: The Last of the Small Molecule Best Sellers?
Forbes just published a list of "Best Selling Drugs of All Time" (see here). I created the following chart from the data cited (click on it for a larger view):"Tellingly," notes the Forbes author, Simon King, "each of the products in the list above best positioned to record an increase in peak annual sales over the next five years is a biologic; Humira, Enbrel, Rituxan, Herceptin and Lantus being the chief candidates. This is driven by a number of factors – the later launch of certain brands, for example – but also illustrates the robustness of leading biologic franchises that do not face direct substitutable generic c...
Source: Pharma Marketing Blog - January 28, 2013 Category: Pharma Commentators Tags: Drug prices Plavix Humira Lipitor Pfizer drug pipeline orphan drugs Blockbuster Source Type: blogs
How Much? Payers And The New Pfizer RA Pill
Two months ago, the FDA approved a pill from Pfizer called Xeljanz that is being used to treat adults with moderately to severely rheumatoid arthritis who did not respond to, or cannot tolerate, methotrexate, a standard of care. Some Wall Streeters expect the drug, which competes with such biologics as Humira, to become a blockbuster.
The drug is the first in a class of medications known as JAK inhibitors for RA and data has indicated the pill would offer similar efficacy to such widely used injectables that, collectively, generate some $13 billion in annual sales for treating rheumatoid arthritis. As noted previously, Xel...
Source: Pharmalot - January 3, 2013 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Abbvie Amgen Enbrel Humira Pfizer Rheumatoid Arthritis Xeljanz Source Type: blogs
AbbVie: The Abbott Spinoff Arrives, But What’s Next?
It is now official – AbbVie exists. For those who may not recall, AbbVie is the so-called research-based pharma that has been spun off by Abbott Laboratories and features a portfolio of existing medicines, such as Humira and Synthroid, along with a pipeline of some 20 compounds in Phase II or Phase III development.
One question, though, is what kind of shelf life will AbbVie actually have? On one hand, there is Humira, a biologic that is approved to treat rheumatoid arthritis, psoriasis and Crohn’s disease, where the average treatment penetration rate is below 20 percent, notes Damien Conover, who heads pharma ...
Source: Pharmalot - January 2, 2013 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Abbott Laboratories Abbvie Humira Pfizer Rheumatoid Arthritis Source Type: blogs
